Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Solidaki E, Chatzi L, Bitsios P, Markatzi I, Plana E, Castro F. Work-related and psychological determinants of multisite musculoskeletal pain. Scand J Work Environ Health. 2010 Jan;36(1):54-61.
Bradley RH, National Institute of Child Health and Human Development (NICHD) Early Child Care Research Network, McLeod LD. Child care and common communicable illnesses in children aged 37 to 54 months. Arch Pediatr Adolesc. 2003 Feb;157(2):196-200. doi: 10.1001/archpedi.157.2.196
Rothman KJ. Cancer occurrence among workers exposed to acrylonitrile. Scand J Work Environ Health. 1994 Jan 1;20(5):313-21. doi: 10.5271/sjweh.1391
Lanes SF, Rothman KJ, Dreyer NA, Soden KJ. Mortality update of cellulose fiber production workers. Scand J Work Environ Health. 1993 Jan 1;19(6):426-8.
Walker AM, Cohen AJ, Loughlin JE, Rothman KJ, Defonso LR. Mortality from cancer of the colon or rectum among workers exposed to acrylate and methyl methacrylate. Scand J Work Environ Health. 1991 Jan 1;17(1):7-19.
Lanes SF, Cohen A, Rothman KJ, Dreyer NA, Soden KJ. Mortality of cellulose fiber production workers. Scand J Work Environ Health. 1990 Aug 1;16(4):247-51.